Community-acquired Pneumonia Clinical Trial
Official title:
Evaluation of the Safety and Efficacy of Silmitasertib (CX-4945) in Combination With Standard of Care (SOC) for Treating Patients With Community-Acquired Pneumonia (CAP) Associated With SARS-CoV-2 and Influenza Viral Infections
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated pneumonia. The subjects will be recruited into two domains, including SARS-CoV-2 and influenza virus domains. The study will compare the efficacy of Standard of Care (SOC) combined with CX-4945 against SOC paired with a placebo, utilizing a 1:1 allocation ratio in each domain.
Domain I: SARS-CoV-2 domain - Arm 1: CX-4945 (400 mg BID for 5 days) +SOC - Arm 2: Placebo + SOC Domain II: Influenza virus domain - Arm 3: CX-4945 (400 mg BID for 5 days) +SOC - Arm 4: Placebo + SOC After screening visit, eligible subjects who fulfill all selection criteria for enrollment will be randomized into each of the arms. CX-4945 will be administered at 400 mg BID for up to 5 days. After treatment phase, subjects will be followed up for 28 days. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05722938 -
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
|
Phase 3 | |
| Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
| Recruiting |
NCT06065618 -
Characteristics of Hospitalized Patients With Community-acquired Pneumonia
|
||
| Not yet recruiting |
NCT03675178 -
Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia
|
Phase 4 | |
| Not yet recruiting |
NCT04166110 -
Antibiotic Therapy In Respiratory Tract Infections
|
N/A | |
| Completed |
NCT02380352 -
Short-course Antimicrobial Therapy for Paediatric Respiratory Infections
|
Phase 4 | |
| Completed |
NCT01671280 -
Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
|
N/A | |
| Completed |
NCT02555852 -
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
|
N/A | |
| Recruiting |
NCT00752947 -
Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
|
Phase 4 | |
| Completed |
NCT00140023 -
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
|
Phase 3 | |
| Recruiting |
NCT04089787 -
Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia
|
Phase 4 | |
| Completed |
NCT05356494 -
Postural Drainage and PEP Technique in Community Acquired Pneumonia
|
N/A | |
| Completed |
NCT05133752 -
Oral Nemonoxacin in Treating Elderly Patients With CAP
|
Phase 4 | |
| Not yet recruiting |
NCT06291012 -
Stopping Pneumonia Antibiotherapy Regimen Early
|
Phase 4 | |
| Recruiting |
NCT05002192 -
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
|
||
| Completed |
NCT03452826 -
Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia
|
N/A | |
| Terminated |
NCT04071041 -
Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.
|
Phase 3 | |
| Completed |
NCT03474991 -
KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP
|
Phase 3 | |
| Withdrawn |
NCT01662258 -
Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP
|
N/A | |
| Completed |
NCT01683487 -
Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.
|
Phase 4 |